Oncogenic Kras targeting with MRTX1133 or Daraxonrasib specifically synergize with anti-CTLA4 to promote anti-tumor immunity in pancreatic cancer
It is shown that KRAS targeting with MRTX1133 or Daraxonrasib specifically synergizes with anti-CTLA4, but not other immune checkpoint inhibitors, in inducing tertiary lymphoid structures and promoting anti-tumor immune responses in preclinical pancreatic cancer models.